2020
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome
Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leukemia & Lymphoma 2020, 62: 1187-1194. PMID: 33356689, PMCID: PMC8106643, DOI: 10.1080/10428194.2020.1861270.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBortezomibHumansHydroxamic AcidsLeukemia, Myeloid, AcuteMyelodysplastic SyndromesSulfonamidesTreatment OutcomeConceptsStable diseaseAcute leukemiaDay 1Phase 1 dose-escalation studyRefractory acute leukemiaDose-escalation studyPhase 1 studyWhole-exome sequencingComplete pathologicKaryotypic responseAdult patientsQTc prolongationFirst patientMyelodysplastic syndromeTreatment strategiesBlast crisisPatientsExceptional responseKaryotypic aberrationsBelinostatGood responseBortezomibAMLLeukemiaFurther investigation
1985
Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia
Roberts JD, Ershler WB, Tindle BH, Stewart JA. Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. Cancer 1985, 56: 1001-1005. PMID: 3860278, DOI: 10.1002/1097-0142(19850901)56:5<1001::aid-cncr2820560504>3.0.co;2-p.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBone MarrowCytarabineFemaleHumansLeukemia, Myeloid, AcuteLeukopeniaMaleMyeloproliferative DisordersThrombocytopeniaConceptsLow-dose cytosineAcute myelogenous leukemiaMyelodysplastic syndromeMyelogenous leukemiaTransient hematologic toxicityPeripheral blood countsAppropriate clinical roleTransfusion requirementsHematologic toxicityPartial responseDecreased incidenceBlood countClinical roleLow dosagePatientsSyndromeLeukemiaInfectionIncidenceCessation